GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated November 13, 2024, reports on the status of the company's employee share schemes for the six-month period from May 1, 2024, to October 31, 2024. The document serves as a regulatory disclosure of block listing returns for specific equity incentive plans.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details the movement of unallotted securities under three specific share schemes:
- GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan: 115,518 unallotted securities at the start and end of the period; no new issuances.
- GlaxoSmithKline plc Share Save Plan 2012: Started with 673,024 unallotted securities; 155,786 were issued/allotted during the period, leaving a balance of 517,238.
- GlaxoSmithKline plc Share Save Plan 2022: Started with 995,257 unallotted securities; 19,867 were issued/allotted during the period, leaving a balance of 975,390.
Material Changes
There were no increases applied for to the block schemes during the reporting period. The only material changes were the allotment of securities under the Share Save Plan 2012 and Share Save Plan 2022, reducing the respective balances of unallotted shares.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a statutory return regarding share scheme administration.
Key Facts for Investor Verification
- Verify the total number of shares issued under the Share Save Plan 2012 (155,786) and Share Save Plan 2022 (19,867) against the company's broader equity compensation disclosures.
- Confirm that no new share blocks were authorized for any of the three schemes during the six-month period.
- Note that the Deferred Annual Bonus Plan remained static with no issuances.